Profile of abemaciclib and its potential in the treatment of breast cancer.

Abstract:

:Hormone-receptor-positive breast cancer is the most common subtype of breast cancer among patients with both early-stage and metastatic disease. Recent advances in the understanding of its pathophysiology have led to the discovery and utilization of targeted inhibitors to cyclin-dependent kinases 4 and 6 (CDK4/6). There are currently three available CDK4/6 inhibitors available for use in USA: palbociclib, ribociclib, and abemaciclib. Their oral administration and tolerable toxicities make this class of agents appealing to both patients and health care providers. Abemaciclib, the most recently approved CDK4/6 inhibitor, has unique pharmacologic properties and potential toxicities. This review highlights the current understanding of abemaciclib and discusses its current and future roles in the treatment of breast cancer.

journal_name

Onco Targets Ther

journal_title

OncoTargets and therapy

authors

Martin JM,Goldstein LJ

doi

10.2147/OTT.S149245

subject

Has Abstract

pub_date

2018-08-29 00:00:00

pages

5253-5259

issn

1178-6930

pii

ott-11-5253

journal_volume

11

pub_type

杂志文章,评审